Enovis (ENOV) news
Recent news
Enovis Corporation: Needham cuts target price to $34 from $52
Needham & Company has revised its price target for Enovis Corporation (NYSE: EOV), reducing it from $52 to $34, according to a recent analyst note. The adjustment reflects a reassessment of the company’s near-term outlook and market dynamics. The firm maintains its position on the stock but has…
AInvest Wire · 3d agoMassimo Group - Company to pay $15,000 per month cash compensation under agreement - SEC filing
Orthofix Medical Inc. has announced that Massimo Calafiore will assume the role of President and Chief Executive Officer in early 2024, following the completion of LimaCorporate S.p.A.’s acquisition by Enovis Corporation. The appointment was approved by the company’s Board of Directors and outlined…
AInvest Wire · Sep 30, 2026Enovis climbs to session-high 8% after conference presentation
Enovis shares rose to a session high of 8% following a presentation at a recent industry conference, where the company outlined strategic advancements in its orthopedic and medical technology segments. The presentation highlighted progress in product development and operational efficiency, which…
AInvest Wire · Sep 8, 2026Ecentral Robotics announces binding offer from Enovis
Ecentral Robotics has announced that it has entered into a binding offer agreement with Enovis, a global diversified medical technology company. Under the terms of the agreement, Enovis will acquire Ecentral Robotics, a move that is expected to expand Enovis’s portfolio in the medical technology…
AInvest Wire · Sep 1, 2026Enovis: Expect about 150 bps of deal related dilution to adj EBITDA margin in 2027, offset by about 50 bps of underlying improvement
Enovis Corporation (NYSE: ENOV) has outlined expectations for approximately 150 basis points (bps) of deal-related dilution to its adjusted EBITDA margin in 2027, according to recent guidance. This projection is primarily attributed to the integration of recent acquisitions and the associated…
AInvest Wire · Sep 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.